Advances in treatment of alveolar soft part sarcoma: an updated review
Japanese Journal of Clinical Oncology · 05.11.2023 · 53 (11) · 1009-1018
DOI: 10.1093/jjco/hyad102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 25.08.2023. Verfasst von Tomohiro Fujiwara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Sarcoma, Alveolar Soft Part, Soft Tissue Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Alveolar soft part sarcoma is a rare neoplasm of uncertain histogenesis that belongs to a newly defined category of ultra-rare sarcomas. The neoplasm is characterized by a specific chromosomal translocation, der (17) t(X; 17)(p11.2;q25), that results in ASPSCR1–TFE3 gene fusion. The natural history of alveolar soft part sarcoma describes indolent behaviour with slow progression in deep soft tissues of the extremities, trunk and head/neck in adolescents and young adults. A high rate of detection of distant metastasis at presentation has been reported, and the most common metastatic sites in decreasing order of frequency are the lung, bone and brain. Complete surgical resection remains the standard treatment strategy, whereas radiotherapy is indicated for patients with inadequate surgical margins or unresectable tumours. Although alveolar soft part sarcoma is refractory to conventional doxorubicin-based chemotherapy, monotherapy or combination therapy using tyrosine kinase inhibitors and immune checkpoint inhibitors have provided antitumor activity and emerged as new treatment strategies. This article provides an overview of the current understanding of this ultra-rare sarcoma and recent advancements in treatments according to the clinical stage of alveolar soft part sarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Department of Pathology, Okayama University Hospital, Okayama, Japan.
- Department of Orthopaedic Surgery, Mie University, Tsu, Japan.
- Department of Advanced Medical Sciences, Oita University, Yufu, Japan.
ORCID-Profile: Tomohiro Fujiwara, Toshiyuki Kunisada, Eiji Nakata, Tomoki Nakamura, Kazuhiro Tanaka
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fujiwara, T., Kunisada, T., Nakata, E., Nishida, K., Yanai, H., Nakamura, T., Tanaka, K., & Ozaki, T. (2023). Advances in treatment of alveolar soft part sarcoma: an updated review. Japanese Journal of Clinical Oncology, 53(11), 1009-1018. https://doi.org/10.1093/jjco/hyad102
Vancouver
Fujiwara T, Kunisada T, Nakata E, Nishida K, Yanai H, Nakamura T, et al. Advances in treatment of alveolar soft part sarcoma: an updated review. Japanese Journal of Clinical Oncology. 2023;53(11):1009-1018. doi:10.1093/jjco/hyad102
BibTeX
@article{Fujiwara2023,
author = {Fujiwara, Tomohiro and Kunisada, Toshiyuki and Nakata, Eiji and Nishida, Kenji and Yanai, Hiroyuki and Nakamura, Tomoki and Tanaka, Kazuhiro and Ozaki, Toshifumi},
title = {Advances in treatment of alveolar soft part sarcoma: an updated review},
journal = {Japanese Journal of Clinical Oncology},
year = {2023},
volume = {53},
number = {11},
pages = {1009--1018},
doi = {10.1093/jjco/hyad102}
}
EUVIMED